Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accelerated approval

Roche - Basel

Roche wins European approval for new leukaemia drug

Gazyvaro now available for use in treatment of blood cancer in the EU

- PMLiVE

J&J’s Imbruvica wins new cancer indication

FDA backs drug’s use in chronic lymphocytic leukaemia patients with genetic mutation

Novartis building

Novartis’ glaucoma combo cleared in Europe

Simbrinza approved to treat eye condition

- PMLiVE

AZ signs two companion diagnostic deals

Will help identify patients suitable for treatment with lung cancer drugs

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Nexavar fails late-stage breast cancer trial

Bayer’s oncology drug unable to improve progression free survival in new indication

- PMLiVE

FDA approves Gilead drug in three blood cancers

Zydelig recommended for use in chronic lymphocytic leukaemia and two forms of lymphoma

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

- PMLiVE

Lilly steps up cancer immunotherapy research

Agrees development deal with Immunocore

- PMLiVE

Priority review for Roche’s Avastin in cervical cancer

Will speed up FDA assessment of oncology drug

Roche - Basel

Roche’s MEK inhibitor boosts Zelboraf efficacy in melanoma

Could give edge to Swiss company as new skin cancer treatments see growth

- PMLiVE

Eisai’s Bose to join Boehringer

He becomes head of global marketing for oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links